> ## Content Index
> Fetch the complete content index at: https://www.theamericanquorum.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Restricts Johnson & Johnson COVID-19 Vaccine After 60 Confirmed TTS Cases and 9 Deaths
- URL: https://www.theamericanquorum.com/taq-historical-2022-05-07-healthcare/
- Published: 2022-05-08T03:59:00.000Z
- Updated: 2022-05-08T03:59:00.000Z
- Description: FDA has limited the Johnson & Johnson COVID-19 vaccine to adults who cannot receive other vaccines or would otherwise remain unvaccinated after updated TTS safety data.
- Author: Kenneth R. Deans Jr.
- Tags: Healthcare, #Import 2026-08-31 12:02

The Food and Drug Administration has sharply restricted use of Johnson & Johnson’s COVID-19 vaccine after an updated federal safety review identified 60 confirmed cases of thrombosis with thrombocytopenia syndrome, including nine deaths, following roughly 18 million administered doses. The single-dose vaccine is now authorized primarily for adults who cannot receive another available COVID-19 vaccine for medical or access reasons, or who would otherwise decline vaccination.

The FDA’s [May 5 decision memorandum](https://www.fda.gov/media/158318/download?ref=theamericanquorum.com) reports a TTS rate of 3.23 cases per million Janssen doses and a TTS death rate of 0.48 per million. The rare syndrome combines serious blood clots with low platelet counts, typically emerging one to two weeks after vaccination. Regulators concluded that the risk remains persistent and that widespread availability of mRNA vaccines changes the benefit-risk calculation for people who have other options.

## The authorization narrows after more than a year of surveillance

Under the revised authorization, the Janssen vaccine remains available to adults for whom Pfizer-BioNTech or Moderna vaccination is not accessible or clinically appropriate, including people with certain contraindications. It also remains an option for adults who understand the identified safety risk and would otherwise choose not to be vaccinated. The FDA’s [May 5 announcement](https://www.fda.gov/news-events/press-announcements/actualizacion-sobre-el-coronavirus-covid-19-la-fda-limita-el-uso-de-la-vacuna-contra-el-covid-19-de?ref=theamericanquorum.com) says the restriction follows an updated analysis of cases reported through March 18.

The revised federal posture is a significant change from February 2021, when the one-dose product was viewed as a major logistical advantage for mobile clinics, rural communities and people unlikely to return for a second appointment. Johnson & Johnson’s original [authorization announcement](https://www.jnj.com/media-center/press-releases/johnson-johnson-covid-19-vaccine-authorized-by-u-s-fda-for-emergency-usefirst-single-shot-vaccine-in-fight-against-global-pandemic?ref=theamericanquorum.com) emphasized the simplicity of a single injection and standard refrigerator storage, attributes expected to expand the reach of the vaccination campaign.

Safety concerns emerged within weeks of broad use. Federal officials temporarily paused the vaccine in April 2021 after reports of unusual clotting events, then resumed use with warnings. Continued surveillance subsequently identified additional cases and deaths, preventing regulators from treating the initial signal as a short-lived anomaly.

## CDC had already moved mRNA vaccines to the front

The FDA action follows a December recommendation from the CDC’s Advisory Committee on Immunization Practices that mRNA vaccines be preferred over the Janssen product for adults. A detailed [MMWR review](https://www.cdc.gov/mmwr/volumes/71/wr/mm7103a4.htm?ref=theamericanquorum.com) published in January describes the committee’s unanimous 15-0 vote and its assessment of TTS, Guillain-Barré syndrome, vaccine effectiveness and the wide availability of alternative vaccines.

At the committee’s [December 16 meeting](https://archive.cdc.gov/www%5Fcdc%5Fgov/vaccines/acip/meetings/live-mtg-2021-12-16.html?ref=theamericanquorum.com), federal safety specialists presented updated TTS data and a new benefit-risk analysis. Members concluded that Janssen could still be appropriate in limited situations, such as a contraindication to mRNA vaccines, but that Pfizer and Moderna should generally be used when available.

The distinction is important because FDA and CDC perform different roles. FDA determines whether and under what conditions a vaccine may be authorized, while CDC recommendations guide clinical use within that authorization. The latest decision aligns the legal authorization more closely with the clinical preference CDC established months earlier.

## Risk remains rare but can be severe

The absolute risk of TTS is very small, but federal officials are placing particular weight on its severity and the existence of safer alternatives. The updated FDA analysis found the highest reporting rates among women ages 30–49, though cases have occurred in both women and men across a broad adult age range. Half of the 60 confirmed cases involved cerebral venous sinus thrombosis, and all resulted in hospitalization.

[The Washington Post reported](https://www.washingtonpost.com/health/2022/05/05/fda-johnson-and-johnson-vaccine/?ref=theamericanquorum.com) that FDA vaccine chief Peter Marks characterized the issue as a persistent safety signal rather than a newly discovered one. He said regulators had hoped to identify a way to predict which recipients were most vulnerable but had not found a reliable mitigation strategy beyond limiting use.

The updated safety information should not alarm people who received the vaccine months ago. TTS generally occurs within the first several weeks after vaccination, not as a delayed complication many months later. The revised policy is therefore aimed at future vaccine choices rather than people with past Janssen doses who remain well.

## Johnson & Johnson says the vaccine still has a role

Johnson & Johnson said the safety language in its U.S. fact sheet has been strengthened and that the vaccine retains a favorable benefit-risk profile compared with remaining unvaccinated. In a [May 5 company statement](https://www.jnj.com/media-center/press-releases/johnson-johnson-updates-u-s-covid-19-vaccine-fact-sheet?ref=theamericanquorum.com), the manufacturer acknowledged the revised authorization and emphasized that TTS is rare but potentially life-threatening.

The vaccine’s continuing availability is meaningful for a small number of people. Some have had severe allergic reactions to components of mRNA vaccines. Others may lack practical access to those vaccines or prefer the Janssen product strongly enough that restricting it entirely could result in no vaccination at all. The FDA has therefore chosen a narrower authorization rather than withdrawal.

[Associated Press reporting](https://www.pbs.org/newshour/health/fda-restricts-johnson-johnsons-covid-19-vaccine-due-to-blood-clot-risk?ref=theamericanquorum.com) notes that the single-shot vaccine has already played a much smaller role in the U.S. campaign than Pfizer and Moderna. About 18.7 million Janssen doses had been administered, compared with hundreds of millions of mRNA doses, reducing the operational impact of the restriction even as its regulatory significance is substantial.

The decision illustrates how vaccine policy evolves as rare events become visible only after millions of doses. Janssen remains an effective COVID-19 vaccine for many recipients, but regulators now have enough post-authorization evidence—and enough alternatives—to conclude that its rare clotting risk should limit routine use. For most adults beginning or continuing COVID-19 vaccination, the federal recommendation is now unambiguous: an mRNA vaccine should be the default choice when it can be used.